As Bluebird Bio (BLUE) Shares Rose, Holder Armistice Capital Raised Position; Signaturefd Maintains Stake in General Electric Co (GE)

January 20, 2018 - By Vivian Currie

Armistice Capital Llc increased its stake in Bluebird Bio Inc (BLUE) by 35.71% based on its latest 2017Q3 regulatory filing with the SEC. Armistice Capital Llc bought 10,000 shares as the company’s stock rose 6.94% with the market. The institutional investor held 38,000 shares of the health care company at the end of 2017Q3, valued at $5.22M, up from 28,000 at the end of the previous reported quarter. Armistice Capital Llc who had been investing in Bluebird Bio Inc for a number of months, seems to be bullish on the $8.06 billion market cap company. The stock decreased 3.38% or $6.15 during the last trading session, reaching $175.95. About 739,632 shares traded. bluebird bio, Inc. (NASDAQ:BLUE) has risen 112.34% since January 20, 2017 and is uptrending. It has outperformed by 95.64% the S&P500.

Signaturefd Llc increased its stake in General Electric Co (GE) by 19.31% based on its latest 2017Q3 regulatory filing with the SEC. Signaturefd Llc bought 16,718 shares as the company’s stock declined 7.64% while stock markets rallied. The institutional investor held 103,317 shares of the consumer electronics and appliances company at the end of 2017Q3, valued at $2.50 million, up from 86,599 at the end of the previous reported quarter. Signaturefd Llc who had been investing in General Electric Co for a number of months, seems to be bullish on the $141.01B market cap company. The stock decreased 3.04% or $0.51 during the last trading session, reaching $16.26. About 214.95M shares traded or 136.20% up from the average. General Electric Company (NYSE:GE) has declined 4.46% since January 20, 2017 and is downtrending. It has underperformed by 21.16% the S&P500.

Investors sentiment increased to 1.79 in 2017 Q3. Its up 0.11, from 1.68 in 2017Q2. It is positive, as 35 investors sold BLUE shares while 42 reduced holdings. 45 funds opened positions while 93 raised stakes. 49.05 million shares or 2.37% more from 47.91 million shares in 2017Q2 were reported. Massachusetts-based Tekla Cap Limited Liability Com has invested 0.07% in bluebird bio, Inc. (NASDAQ:BLUE). Fmr Limited Liability Corporation accumulated 6.84M shares or 0.11% of the stock. 3,982 are held by Sg Americas Limited Liability. Dimensional Fund Advisors LP has invested 0.01% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE). Congress Asset Management Communication Ma, a Massachusetts-based fund reported 15,909 shares. Moreover, Mngmt Inc has 0% invested in bluebird bio, Inc. (NASDAQ:BLUE). Meeder Asset Mgmt holds 29 shares. Proshare Advisors stated it has 0.04% of its portfolio in bluebird bio, Inc. (NASDAQ:BLUE). Winfield Associate owns 3,310 shares or 0.24% of their US portfolio. Sivik Global Healthcare Limited Liability stated it has 0.82% in bluebird bio, Inc. (NASDAQ:BLUE). Cim Mangement has 0.11% invested in bluebird bio, Inc. (NASDAQ:BLUE). Citigroup Incorporated owns 41,652 shares or 0% of their US portfolio. Rhumbline Advisers holds 0.02% in bluebird bio, Inc. (NASDAQ:BLUE) or 61,149 shares. Blackrock, New York-based fund reported 3.60M shares. Dupont Cap Mngmt stated it has 8,082 shares or 0.03% of all its holdings.

Among 25 analysts covering bluebird bio (NASDAQ:BLUE), 15 have Buy rating, 2 Sell and 8 Hold. Therefore 60% are positive. bluebird bio had 79 analyst reports since August 11, 2015 according to SRatingsIntel. As per Thursday, August 31, the company rating was maintained by BMO Capital Markets. The rating was maintained by Cantor Fitzgerald with “Sell” on Monday, July 24. The firm has “In-Line” rating given on Monday, November 6 by Evercore. BTIG Research maintained the stock with “Hold” rating in Thursday, August 3 report. The rating was maintained by Oppenheimer with “Hold” on Tuesday, January 9. Standpoint Research downgraded the stock to “Reduce” rating in Friday, June 16 report. The rating was downgraded by Morgan Stanley to “Underweight” on Monday, October 2. The stock of bluebird bio, Inc. (NASDAQ:BLUE) earned “Hold” rating by Oppenheimer on Wednesday, December 20. As per Tuesday, October 20, the company rating was initiated by Oppenheimer. The company was downgraded on Monday, February 27 by Maxim Group.

Armistice Capital Llc, which manages about $848.92M US Long portfolio, decreased its stake in Enanta Pharmaceuticals Inc (NASDAQ:ENTA) by 156,000 shares to 108,000 shares, valued at $5.05 million in 2017Q3, according to the filing. It also reduced its holding in Madrigal Pharmaceuticals Inc by 70,000 shares in the quarter, leaving it with 212,000 shares, and cut its stake in Hanesbrands Inc (NYSE:HBI).

Since August 8, 2017, it had 2 buys, and 1 insider sale for $4.48 million activity. 100,000 General Electric Company (NYSE:GE) shares with value of $2.46M were bought by TISCH JAMES S. On Wednesday, August 9 the insider Comstock Elizabeth J sold $633,375.

Among 27 analysts covering General Electric Company (NYSE:GE), 10 have Buy rating, 5 Sell and 12 Hold. Therefore 37% are positive. General Electric Company had 82 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets on Friday, September 15 with “Buy”. The stock has “Hold” rating by Vetr on Tuesday, September 22. Credit Suisse upgraded the stock to “Focus List” rating in Wednesday, September 16 report. Cowen & Co maintained General Electric Company (NYSE:GE) on Monday, June 12 with “Hold” rating. RBC Capital Markets maintained General Electric Company (NYSE:GE) rating on Monday, November 30. RBC Capital Markets has “Outperform” rating and $34 target. Bernstein upgraded the stock to “Outperform” rating in Friday, December 16 report. The firm has “Market Perform” rating given on Tuesday, July 26 by Bernstein. The stock of General Electric Company (NYSE:GE) has “Hold” rating given on Monday, August 7 by Cowen & Co. JP Morgan maintained it with “Underweight” rating and $17 target in Wednesday, November 1 report. J.P. Morgan maintained the stock with “Sell” rating in Monday, October 9 report.

Investors sentiment decreased to 0.69 in 2017 Q3. Its down 0.10, from 0.79 in 2017Q2. It fall, as 112 investors sold GE shares while 818 reduced holdings. 118 funds opened positions while 525 raised stakes. 4.70 billion shares or 1.82% more from 4.61 billion shares in 2017Q2 were reported. 2.85 million were reported by Panagora Asset Management. Calamos Advisors Lc has invested 0.58% in General Electric Company (NYSE:GE). Chemical Bancorp holds 272,390 shares. Roof Eidam And Maycock Adv has 0.45% invested in General Electric Company (NYSE:GE). Copeland Cap Limited Liability Company invested 0.06% in General Electric Company (NYSE:GE). Carlson Cap Mngmt owns 15,402 shares. First Pacific Advisors Limited Com reported 9.76 million shares. Japan-based Tokio Marine Asset Management Ltd has invested 0.27% in General Electric Company (NYSE:GE). Citadel Advsrs Lc holds 0.03% or 1.38 million shares. High Pointe Capital Management Ltd Llc has 1.45% invested in General Electric Company (NYSE:GE) for 41,050 shares. Acropolis Investment Mngmt Limited Liability Company accumulated 7,620 shares. Cove Street Limited Liability Company has 373,700 shares for 1.01% of their portfolio. 1St Source Bankshares, a Indiana-based fund reported 243,465 shares. Chesley Taft & Assocs reported 495,412 shares stake. Winslow Evans & Crocker Inc accumulated 82,470 shares.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>